



Information on the total number of voting rights and shares comprising the share capital on May 6, 2024

*Article R.22-10-23 of the French commercial code
Lyon – France*

In the context of its combined Annual General Meeting on May 28, 2024, in compliance with article R. 22-10-23 of the French Commercial Code, **MaaT Pharma (EURONEXT: MAAT – the “Company”)** hereby declares the number of shares comprising the share capital and the total number of voting rights (Article L. 233-8 of the French Commercial Code (Code de commerce) and Article 223-16 of the General Regulations of French Autorité des Marchés Financiers (AMF)) on May 6, 2024 (ie on publication date of the notice of meeting).

Listing place: Euronext Paris

ISIN code: FR0012634822

Website: www.maatpharma.com

Date	Total number of shares comprising the share capital	Total number of theoretical voting rights ⁽¹⁾	Total number of effective voting rights ⁽²⁾
05/06/2024	11 623 653	11 623 653	11 602 758

(1) In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.

(2) Effective voting rights correspond to the total number of voting rights that may be used at a General Meeting. The total number of effective voting rights is calculated without taking into account the shares with suspended voting rights.